Context Therapeutics (CNTX) risk factors
Item 1A of every Context Therapeutics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors64 risks9 new12 dropped13 reworded
Context Therapeutics added major risks concerning U.S. trade policies, tariffs, FDA companion diagnostics, and federal regulatory agency changes under the Department of Government Efficiency. The company continues to depend heavily on the clinical development of its pipeline products CTIM-76, CT-95, and CT-202.
Filed Mar 23, 2026 - FY2024 10-K risk factors67 risks
Context Therapeutics is an early-stage biopharmaceutical company dependent on raising capital to fund development of its key therapeutic candidates CTIM-76, CT-95, and CT-202. The company relies on a small team of twelve employees and external third-party manufacturers and collaborators.
Filed Mar 20, 2025